Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk?

Mediastinum · 2019 · PMC6788636 · PMID 31608320

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

fairly significantno p-value reported

Third, since a fairly significant proportion of patients with thymoma (30–40%) have autoimmune disorders at diagnosis, can TET patients with pre-existing paraneoplastic autoimmunity be safely treated with immunotherapy without being placed at risk for a life-threatening flare of the preexisting autoimmune condition upon initiation of immunotherapy?

also in 581 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.